A dose escalation and cohort expansion phase I/IIa study of ACR246, an innovative 5T4- antibody drug conjugate (ADC), in patients (pts) with advanced solid tumors.
Authors: Panpan Zhang, Yunsheng Huang, Lina Chen, Feng Wang, Zhenwei Miao
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.tps3166
Source:
Full article
Abstract
TPS3166